Annual report pursuant to Section 13 and 15(d)

Consolidated Statement of Equity Consolidated Statement of Equity

v3.19.2
Consolidated Statement of Equity Consolidated Statement of Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Retained Earnings
Non-controlling Interests
Accumulated Other Comprehensive Income (Loss)
Directors
Common Stock
Employees
Common Stock
Executive Officers
Common Stock
Balance, beginning of period, shares at Mar. 31, 2016   32,222,720              
Balance, beginning of period at Mar. 31, 2016 $ 298,701 $ 32 $ 216,701 $ 122,258 $ 4,279 $ (44,569)      
Issuance of common stock in exercise of stock options, shares 111,611 43,121              
Issuance of common stock in exercise of stock options $ 250   250            
Issuance of restricted stock as deferred compensation to employees and directors, shares             19,824    
Issuance of common stock in lieu of compensation, shares               47,179 32,709
Stock compensation expense 3,402   3,402            
Excess tax deduction from stock options (1,069)   (1,069)            
Net income (loss) 14,641     14,641          
Foreign curency translation adjustment (4,536)         (4,536)      
Interest rate swap 791         791      
Other (21)         (21)      
Income attributable to non-controlling interests 343       343        
Balance, end of period, shares at Mar. 31, 2017   32,365,553.000              
Balance, end of period at Mar. 31, 2017 312,502 $ 32 219,284 136,899 4,622 (48,335)      
Issuance of common stock in exercise of stock options, shares   42,636              
Issuance of common stock in exercise of stock options $ 300   300            
Issuance of restricted stock as deferred compensation to employees and directors, shares 20,216           20,216    
Issuance of common stock in lieu of compensation, shares               43,445 20,489
Stock compensation expense $ 3,519   3,519            
Excess tax deduction from stock options (481)   (481)            
Net income (loss) 11,913     11,913          
Foreign curency translation adjustment 12,030         12,030      
Interest rate swap 34         34      
Other (270)         (270)      
Income attributable to non-controlling interests $ 1,306       1,306        
Balance, end of period, shares at Mar. 31, 2018 32,492,339 32,492,339.000              
Balance, end of period at Mar. 31, 2018 $ 340,853 $ 32 222,622 148,812 5,928 (36,541)      
Issuance of common stock in exercise of stock options, shares   37,906              
Issuance of common stock in exercise of stock options 396   396            
Issuance of restricted stock as deferred compensation to employees and directors, shares   20,064         20,064    
Issuance of common stock in lieu of compensation, shares               51,775 22,116
Issuance of common stock as deferred compensation to employees 1 $ 1              
Stock compensation expense 4,148   4,148            
Excess tax deduction from stock options (598)   (598)            
Net income (loss) 22,756     22,756          
Foreign curency translation adjustment (13,233)         (13,233)      
Other 825         825      
Remeasurement of non-controlling interest 0   (3,528)   3,528        
Purchase of non-controlling interest (5,665)       (5,665)        
Distribution to non-controlling interest (947)     (947)          
Income attributable to non-controlling interests $ 413       413        
Balance, end of period, shares at Mar. 31, 2019 32,624,200 32,624,200.0              
Balance, end of period at Mar. 31, 2019 $ 348,949 $ 33 $ 223,040 $ 170,621 $ 4,204 $ (48,949)